US Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers, 2019-2023

Highlights

• Comprehensive 620-page analysis of the US tumor marker testing market.
• Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
• Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
• Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.
• Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.
• Current instrumentation technologies and feature comparison of leading analyzers.
• Sales and market shares of leading suppliers.
• Emerging diagnostic technologies and their potential market applications.
• Product development opportunities.
• Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
• Business opportunities and strategic recommendations for suppliers.

I. Introduction
II. Worldwide Market Overview
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
(continues)

VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
(continues)
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
(continues)

29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
(continues)
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
(continues)
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
(continues)
VIII. USA Cancer Diagnostics Market
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment,
Major Supplier Sales and Market Shares by Test
IX. Competitive Profiles
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
(continues)
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Thermo
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila

X. Appendix: Major Universities and Research
Centers Developing Cancer Diagnostic
Technologies and Applications

List Of Tables

Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
(continues)
Major Companies Developing or Marketing
HCG Tests

Major Companies Developing or Marketing
Insulin Tests

Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
(continues)
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis

Executive Summary Table: U.S., Total Tumor
Marker Test Volume and Sales Forecast
By Market Segment
U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates
Per 100,000 Population
U.S., Laboratories Performing Tumor
Marker Tests by Market Segment
U.S., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.S., Commercial/Private Laboratories
Performing Tumor Marker Tests
By Annual Test Volume
U.S., Physician Office Laboratories
Performing Tumor Marker Tests
By Practice Size
U.S., Total Tumor Marker Test Volume
Forecast by Market Segment

U.S., All Market Segments Major
Tumor Marker Test Volume Forecast
U.S., Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.S., Physician Offices/Group Practices
Major Tumor Marker Test Volume Forecast
U.S., Cancer Clinics Major Tumor
Marker Test Volume Forecast by Test
(continues)
U.S., Total Tumor Marker Sales
Forecast by Market Segment
U.S., All Market Segment Major Tumor
Marker Sales Forecast by Test
U.S., Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test
U.S., Physician Offices/Group Practices
Major Tumor Marker Sales Forecast by Test
U.S., Cancer Clinics Major Tumor
Marker Sales Forecast by Test
U.S., ACTH Test Volume and Diagnostics
Sales Forecast by Market Segment

U.S., AFP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Calcitonin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
(continues)
U.S., CEA Test Volume and Diagnostics
Sales by Market Segment
U.S., Chromogranin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., Colon-specific Antigen Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Cytokeratins Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Estrogen Receptor Test Volume
And Diagnostics Sales Forecast by Market Segment

U.S., Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Interferons Test Volume
And Diagnostics Sales Forecast by Market
Segment
U.S., Interleukins Test Volume
And Diagnostics Sales Forecast
by Market Segment
U.S., Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Nucleolar Test Volume and Diagnostics
Sales Forecast by Market Segment
(continues)
U.S., Occult Blood Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Oncogenes Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Sialic Acid Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
(continues)
U.S., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Thyroglobulin Test
Volume and Diagnostics
Sales Forecast by Market Segment
U.S., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Total Tumor Marker Sales
By Major Supplier
U.S., ACTH Testing Market Diagnostics
Sales by Major Supplier
U.S., AFP Testing Market Diagnostics
Sales by Major Supplier
U.S., Beta-2 Migroblolulin Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 15-3/27.29 Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 125 Testing Market Diagnostics
Sales by Major Supplier
U.S., CEA Testing Market Diagnostics
Sales by Major Supplier
U.S., Ferritin Testing Market
Diagnostics Sales by Major Supplier
(continues)
U.S., HCG Testing Market
Diagnostics Sales by Major Supplier
U.S., Insulin Testing Market
Diagnostics Sales by Major Supplier
U.S., Parathyroid Hormone Testing Market
Diagnostics Sales by Major Supplier
U.S., PAP Testing Market Diagnostics
Sales by Major Supplier
U.S., Progesterone Receptor Testing Market
Diagnostics Sales by Major Supplier
U.S., PSA Testing Market Diagnostics
Sales by Major Supplier

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available